At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety Study of Bintrafusp Alfa in Combination With Other Anti-cancer Therapies in Participants With Locally Advanced or Advanced Cervical Cancer (INTR@PID 046)
In Brief
A Phase 1 clinical trial evaluating M7824, Carboplatin, and 4 other interventions for Cervical Cancer. Completed, enrolled 25 participants across 13 sites in 3 countries.
Detailed Summary
This study was to evaluate the safety and tolerability of bintrafusp alfa in combination with other anti-cancer therapies in participants with locally advanced or advanced cervical cancer.
Study Details
Timeline
Interventions
Participants received bintrafusp alfa until confirmed disease progression, death, unacceptable toxicity and study withdrawal maximum of 2 years (at the discretion of the Investigator).
Carboplatin was administered intravenously as per standard of care.
Paclitaxel was administered intravenously as per standard of care.
Bevacizumab was administrated as indicated for standard of care.
Cisplatin was administered intravenously as per standard of care.
Participants received radiotherapy as per standard of care.